11. DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD). (30th January 2023) Authors: Colombel, J F; Hanauer, S B; Sandborn, W; Sands, B E; Schreiber, S; Danese, S; Kierkus, J; Kulynych, R; Klopocka, M; Lahat, A; Gonciarz, M; Osipenko, M; Borzan, V; Kowalski, M; Saenko, D; Sardinov, R; Kim, S; Bae, Y; Lee, S; Yang, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. (July 2022) Authors: Ananthakrishnan, Ashwin N; Kaplan, Gilaad G; Bernstein, Charles N; Burke, Kristin E; Lochhead, Paul J; Sasson, Alexa N; Agrawal, Manasi; Tiong, Jimmy Ho Tuan; Steinberg, Joshua; Kruis, Wolfgang; Steinwurz, Flavio; Ahuja, Vineet; Ng, Siew C; Rubin, David T; Colombel, Jean-Frederic; Gearry, Richard... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 7(2022) Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn's disease patients: results from im-uniti maintenance study. (17th June 2017) Authors: Sands, B; Gasink, C; Jacobstein, D; Gao, L; Johanns, J; Szapary, P; Colombel, J; Targan, S; Ghosh, S; Sandborn, W Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn's disease (CD). (16th January 2018) Authors: Danese, S; Feagan, B; Sandborn, W; Colombel, J -F; Vermeire, S; Jones, S; Brennan, K; Bornstein, J Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension. (30th January 2023) Authors: Danese, S; Afif, W; Abreu, M; Sandborn, W; Miao, Y; Zhang, H; Panaccione, R; Hisamatsu, T; Scherl, E; Leong, R; Rowbotham, D; Arasaradnam, R; Peyrin-Biroulet, L; Sands, B; Marano, C Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study. (15th January 2020) Authors: Vermeire, S; Sandborn, W; Baert, F; Danese, S; Kobayashi, T; Loftus, E V; Bhatia, S; Kisfalvi, K; Rosario, M; Zhang, W; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S020 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12. (21st January 2022) Authors: Dignass, A; Rubin, D; Bressler, B; Huang, K H; Shipitofsky, N; Germinaro, M; Zhang, H; Johanns, J; Feagan, B; Sandborn, W; Sands, B; Hisamatsu, T; Lichtenstein, G; Panes, J; Allegretti, J Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. OP33 Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study. (27th May 2021) Authors: Sandborn, W; Danese, S; Leszczyszyn, J; Romatowski, J; Altintas, E; Peeva, E; Vincent, M; Reddy, P; Banfield, C; Banerjee, A; Gale, J; Hung, K Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S030 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC. (30th January 2023) Authors: Ghosh, S; Feagan, B; Ott, E; Gasink, C; Marano, C; Miao, Y; Sandborn, W; Danese, S; Abreu, M; Sands, B Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. P281 A serum biomarker panel can accurately identify the presence of mucosal ulcers in patients with Crohn's disease. (15th January 2020) Authors: HOLMER, A; Boland, B; Singh, S; Neill, J; Le, H; Miralles, A; Collins, A; Sandborn, W; Dulai, P Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗